JP2022518235A5 - - Google Patents
Info
- Publication number
- JP2022518235A5 JP2022518235A5 JP2021541606A JP2021541606A JP2022518235A5 JP 2022518235 A5 JP2022518235 A5 JP 2022518235A5 JP 2021541606 A JP2021541606 A JP 2021541606A JP 2021541606 A JP2021541606 A JP 2021541606A JP 2022518235 A5 JP2022518235 A5 JP 2022518235A5
- Authority
- JP
- Japan
- Prior art keywords
- shows
- tumors
- cells
- resistant
- figures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794889P | 2019-01-21 | 2019-01-21 | |
| US62/794,889 | 2019-01-21 | ||
| US201962926384P | 2019-10-25 | 2019-10-25 | |
| US62/926,384 | 2019-10-25 | ||
| EP19306461.5 | 2019-11-12 | ||
| EP19306461 | 2019-11-12 | ||
| PCT/US2020/014019 WO2020154187A1 (en) | 2019-01-21 | 2020-01-17 | Therapeutic rna for advanced stage solid tumor cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518235A JP2022518235A (ja) | 2022-03-14 |
| JP2022518235A5 true JP2022518235A5 (https=) | 2023-02-07 |
Family
ID=69582158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541606A Ceased JP2022518235A (ja) | 2019-01-21 | 2020-01-17 | 進行期固形腫瘍がんの治療用ｒｎａ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220040218A1 (https=) |
| EP (1) | EP3914354A1 (https=) |
| JP (1) | JP2022518235A (https=) |
| KR (1) | KR20210119451A (https=) |
| CN (1) | CN113557060A (https=) |
| AU (1) | AU2020211584A1 (https=) |
| BR (1) | BR112021013887A2 (https=) |
| CA (1) | CA3125773A1 (https=) |
| IL (1) | IL284646A (https=) |
| MX (1) | MX2021008604A (https=) |
| SG (1) | SG11202107395VA (https=) |
| TW (1) | TW202043273A (https=) |
| WO (1) | WO2020154187A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202428301A (zh) | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2020210614A1 (en) * | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1867581B (zh) * | 2003-10-10 | 2012-02-01 | 诺沃挪第克公司 | Il-21衍生物 |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| TWI910495B (zh) * | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| MA47604A (fr) * | 2017-02-21 | 2020-01-01 | Regeneron Pharma | Anticorps anti-pd-1 pour le traitement du cancer du poumon |
| TW202428301A (zh) * | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| WO2020041655A1 (en) * | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
| AU2020210614A1 (en) * | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
| JP7774006B2 (ja) * | 2020-06-22 | 2025-11-20 | イミュナミ ラボラトリーズ プライベート リミティド | 癌治療における使用のための組換えポリペプチド及び組合せ |
| CN117043193A (zh) * | 2021-02-11 | 2023-11-10 | 瑞泽恩制药公司 | 通过施用新辅助pd-1抑制剂治疗癌症的方法 |
| US20250032611A1 (en) * | 2021-11-12 | 2025-01-30 | The Brigham And Women's Hospital, Inc. | Gene editing and engineering stem cells for drug delivery |
-
2020
- 2020-01-17 WO PCT/US2020/014019 patent/WO2020154187A1/en not_active Ceased
- 2020-01-17 TW TW109101807A patent/TW202043273A/zh unknown
- 2020-01-17 KR KR1020217026314A patent/KR20210119451A/ko not_active Ceased
- 2020-01-17 JP JP2021541606A patent/JP2022518235A/ja not_active Ceased
- 2020-01-17 MX MX2021008604A patent/MX2021008604A/es unknown
- 2020-01-17 BR BR112021013887-0A patent/BR112021013887A2/pt not_active Application Discontinuation
- 2020-01-17 CA CA3125773A patent/CA3125773A1/en active Pending
- 2020-01-17 SG SG11202107395VA patent/SG11202107395VA/en unknown
- 2020-01-17 EP EP20705266.3A patent/EP3914354A1/en not_active Withdrawn
- 2020-01-17 AU AU2020211584A patent/AU2020211584A1/en not_active Abandoned
- 2020-01-17 CN CN202080010320.9A patent/CN113557060A/zh active Pending
-
2021
- 2021-07-06 IL IL284646A patent/IL284646A/en unknown
- 2021-07-20 US US17/380,249 patent/US20220040218A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518236A5 (https=) | ||
| Yang et al. | T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems | |
| Taefehshokr et al. | Promising approaches in cancer immunotherapy | |
| US11571469B2 (en) | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression | |
| JP7514231B2 (ja) | 癌を治療するためのプラスミド構築体および使用方法 | |
| EP3591041B1 (en) | ANTICANCER COMPOSITION COMPRISING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE CHECKPOINT INHIBITOR | |
| Dougan et al. | Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity | |
| US20070071759A1 (en) | Antibody-immune cell ligand fusion protein for cancer therapy | |
| KR20170015460A (ko) | 방사선 치료와 조합된 ｐｄ-1 및 ｐｄ-ｌ1에 대한 길항제를 이용하는 암 치료 방법 | |
| JP2022518235A5 (https=) | ||
| EP3552614A1 (en) | Anticancer composition comprising recombinant adenovirus expressing degradation factor for extracellular matrix | |
| US20250205337A1 (en) | Compositions and methods for activating immune cells | |
| Liao et al. | The common costimulatory and coinhibitory signaling molecules in head and neck squamous cell carcinoma | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| Olivera et al. | Regional and intratumoral adoptive T-cell therapy | |
| Mivehchi et al. | Microenvironment-based immunotherapy in oral cancer: a comprehensive review | |
| Kokate | A systematic overview of cancer immunotherapy: an emerging therapy | |
| WO2016119308A1 (zh) | 一种抗肿瘤制剂及其制备方法 | |
| Upham et al. | Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches | |
| US10155024B2 (en) | Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells | |
| CN110464845A (zh) | 一种用于乳腺癌免疫治疗的联合用药物组合及其应用 | |
| CN108815188A (zh) | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 | |
| Chung et al. | Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide | |
| Huang et al. | Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine | |
| TWI734027B (zh) | 用於治療癌症之組合物 |